Re: What PARAMAX Is In The Medical World ... So Far:
Only information available regarding "Paramax" relates to a combination of non-opioid analgesics (acetaminophen, or Tylenol in the US) AND anti-emetics (antidopaminergics such as Reglan in the US).
This combination of medication is primarily indicated for the treatment of migraine, but it may also be indicated whenever combined pain and nausea conditions occur, such as in cancer treatments, or diabetic gastroparesis (delayed emptying of the GI tract).
PARAMAX itself as a brand only exists within the UK under the specific combination of Paracetamol (i.e.: the UK designation of acetaminohen, or "Tylenol", a non-opiate pain medication) and metoclopramide (the generic designation of "Reglan", a dopamine receptor antagonist, a serotonine receptor agonist/antagonist, and a muscarinic receptor agonist, for those out there wanting to refresh their biochemistry college lessons).
In relation to this particular company ("PDMI"), the only relevant connection that might exist between this PARAMAX and the biochemical property related to the eye would exist in the muscarinic properties, which are used in glaucoma to allow the iris sphincter muscles to contract, thus easing the evacuation of circulating fluid that is known to build pressure in the anterior part of the eye in glaucoma patients. For the anatomy and physiology college buff, the fluid of the eye (viscous humor) naturally circulates freely towards a particular angulated anatomy of the eye called the traberculae. If that area is too narrow or closed, contraction of the iris sphincter will open the exit a bit more and further ease the passage of the humor. If the eye is NOT able to do this on its own, then GLAUCOMA results from this particular physiologic anomaly of the eye, and eyedrop (See: pilocarpine) are used to releave the ensuing pressure, visual disturbances, and often pain.
If PDMI's "machine" is called PARAMAX, it would be sort of an awkward coincidence, since the name already exists in a pill.
We would need to wait for further development in this company until the name be revealed with some explanation, since PDMI is also in the business of glaucoma, and that "PARAMAX" precisely claims to be the next revolutionary step for the treatment of this painful, debilitating condition (when not treated).
So, here is a "Black Box Warning": Why choose to market under the name of a pre-existing pill whose side-effects may benefit glaucoma? Would they not have done some market study and realize that this name already exists in pill form?
Let's see what comes out of the PR over the next few weeks. Stay tune.
- Dalcindo (MD)
Disclosure: I have a long position in PDMI
News 
Market Data 
Discover 
